Sidley represented Carlin Consumer Health (“Carlin”), a preeminent consumer health business that specializes in acquiring leading over the counter brands, in its acquisition of Infirst USA Holdings, LLC (“Infirst”), the parent company of Infirst Healthcare Inc.
Infirst is the marketer of two iconic digestive health brands, Mylanta® and Mylicon®, pursuant to a trademark licensing agreement with McNeil Consumer Pharmaceuticals Co., as well as Dr. Cocoa® cough and cold medicine and Ypsomed-branded medical devices. As part of the transaction, Infirst became a wholly owned subsidiary of Carlin.
“We are very excited to be associated with these two great brands,” said Scott Chapman, President and Chief Executive Officer of Carlin. “We believe that Carlin can make important contributions to the continued impressive growth of Infirst, and we look forward to furthering its mission of providing unsurpassed relief for consumer digestive health needs.”
The Sidley team was led by Asher Rubin (Technology and Life Sciences Transactions) and Zachary Shub-Essig (Private Equity), and included Angela Fontana and Joe Zenruffinen (Global Finance); Eric Kauffman (Labor, Employment and Immigration); Stacy Crosnicker and Gregory Matisoff (Employee Benefits and Executive Compensation); and Dusan Clark and Collin Marshall (Technology and Life Sciences Transactions).
For additional information, please refer to the press release.
